” src=”https://s.yimg.com/ny/api/res/1.2/.1lhybLF0W9vVBmWxaTTTw–/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MA–/https://media.zenfs.com/en/investopedia_245/a1afde51eeb0ab652d5829da4c8eec6c” data-src=”https://s.yimg.com/ny/api/res/1.2/.1lhybLF0W9vVBmWxaTTTw–/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MA–/https://media.zenfs.com/en/investopedia_245/a1afde51eeb0ab652d5829da4c8eec6c”>
Posted inBusiness
Edwards Lifesciences Stock Plummeted Today. Here’s Why
Pavlo Gonchar / SOPA Images / LightRocket via Getty Images
Key Takeaways
-
Edwards Lifesciences cut sales-growth estimates for its biggest source of revenue, a heart valve replacement treatment.
-
The heart disease and critical care monitoring company also missed expectations with its second-quarter earnings.
-
Edwards Lifesciences stock lost almost a third of its value on Thursday, the worst performer in the S&P 500.
Edwards Lifesciences (EW) shares swooned Thursday, dropping after the company damped expectations for heart valve replacement sales growth on Wednesday.
The company said it expects full-year sales growth of 5% to 7% for its transcatheter aortic valve replacement (TAVR) treatment, down from the 8% to 10% forecast earlier. TAVR involves replacing a diseased heart valve using a catheter rather than through open-heart surgery.
Full-year sales of transcatheter mitral and tricuspid therapies (TMTT) are expected to come in on the higher end of Edwards’ previously issued range of $320 million to $340 million. The company reiterated its surgical sales growth projection of 6% to 8%.
Shares of Edwards plunged 31% to finish at $59.76 Thursday, leaving them down about 22% this year. The stock was the day’s worst performer in the S&P 500.
In the second quarter, Edwards posted earnings per share (EPS) of 61 cents, falling short of the 74 cents expected by analysts, according to Visible Alpha. Revenue was $1.39 billion, below expectations. TAVR revenue rose 5% year-over-year to $1 billion.
Read the original article on Investopedia.
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel
